Zealand Pharma A/S : First Half 2021 Report

First Half 2021

Report Ÿ

Zealand Pharma

12 August 2021

Forward looking statement

This presentation contains "forward-looking statements", as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, that provide Zealand Pharma's expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products.

The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward- looking statements to be incorrect, and which include, but are not limited to, the occurrence of adverse safety events; risks of unexpected costs or delays; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; product liability claims; and the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations and financial condition.

If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement.

All such forward-looking statements speak only as of the date of this presentation and are based on information available to Zealand Pharma as of the date of this release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

1H 2021 presentation

12 August 2021

2

Zealand Pharma in 2021

Historical year as the company becomes a fully integrated biopharmaceutical company

Launch of Zegalogue® with an optimized commercial team

Execute on our robust late-stage clinical pipeline

Advance our early-stage programs into the clinic

Maintain a strong financial and organizational position

1H 2021 presentation

12 August 2021

3

With the ZEGALOGUE® approval we have taken another important step in pursuing our ambition as a fully integrated biopharmaceutical company

5x25

Have 5 commercialized products by 2025

Optimize commercial operations

Fully operational US infrastructure

High prescriber coverage

Established relationships with KOLs and HCPs

Invest in innovative peptide research platform and robust pipeline

Secure strong financial situation

DKK thousand

1,500,000

1,000,000

500,000

0
2017	2018	2019	2020	1H 2021
Cash & cash equivalents		Restricted cash		Securities

1H 2021 presentation

12 August 2021

4

ZEGALOGUE® provides an attractive treatment option for patients and providers alike

10 Minutes Consistent Recovery

Median time to blood glucose recovery of 10 minutes in adults and children

All pivotal phase 3 studies

reported the same median time to recovery

99% of patients in the main adult phase

3 trial recovered within 15 minutes

• www.zegalogue.com/prescribing-information

1H 2021 presentation

12 August 2021

5